Physician profile
Mirfat Bird
NPI 1225018518
$2,402.67
in general payments reported to CMS, 2019-2025
24 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.49 · 2020: $105 · 2021: $342 · 2022: $671 · 2023: $499 · 2024: $458 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.04 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $202.08 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.81 | 2021-2025 | Caplyta |
| Lilly USA, LLC | $184.50 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $155.01 | 2021-2025 | Airsupra, Breztri |
| Amgen INC. | $145.44 | 2021-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $131.67 | 2021-2023 | |
| Exact Sciences Corporation | $116.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $91.93 | 2019-2022 | |
| Shield Therapeutics INC | $66.12 | 2023-2025 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $63.99 | 2022 | |
| Allergan, INC. | $47.53 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.91 | 2019 | |
| Abbott Laboratories | $28.42 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.66 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $24.98 | 2023 | Seglentis |
| Teva Pharmaceuticals USA, INC. | $23.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $20.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.90 | 2024 | Voquezna |
| Neurocrine Biosciences, INC. | $16.08 | 2024 | Ingrezza |
| Alfasigma USA, INC. | $15.64 | 2021 | |
| Pfizer INC. | $14.05 | 2022 | |
| Eisai INC. | $12.46 | 2021 | |
| Esperion Therapeutics, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirfat Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.